Lexology January 26, 2023
The CBD industry is buzzing with today’s news that the U.S. Food and Drug Administration (FDA) is working with Congress to develop a new regulatory framework for cannabidiol (CBD) products. This is great news for businesses developing CBD products, as it means that there will be a clear path forward for the lawful marketing of these products.
The FDA has convened a high-level internal working group to explore potential regulatory pathways for CBD products. This working group, led by FDA Principal Deputy Commissioner Janet Woodcock, M.D., has closely examined the existing scientific data related to CBD, including studies related to the CBD-based drug Epidiolex, published scientific literature, information submitted to a public docket, and studies both conducted and commissioned by...
Today's Sponsors
Today's Sponsor